Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
ID: 337463Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337463

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-084.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory epidemiologic research focused on emerging risk factors associated with liver cancer, specifically hepatocellular carcinoma and other histological subtypes. This initiative aims to investigate novel hypotheses regarding biological, environmental, and social factors that may contribute to the increasing incidence of liver cancer in the United States, particularly non-viral risk factors such as obesity and environmental toxins. Eligible applicants include a wide range of organizations, and the grant provides funding of up to $275,000 over a two-year period. Interested parties should note that the application deadline is May 7, 2025, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-084.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is offering a funding opportunity for exploratory epidemiologic research on emerging risk factors associated with liver cancer, particularly focusing on biological, environmental, and social factors. This initiative emphasizes the need to investigate the growing incidence of liver cancer in the U.S., especially hepatocellular carcinoma (HCC) and other rare histological subtypes. The funding is aimed at understanding non-viral risk factors like obesity, metabolic syndrome, and environmental toxins, potentially contributing to the increase in liver cancer cases. The R21 grant allows for a budget of up to $275,000 over a two-year period, with application submissions encouraged from a variety of eligible organizations, including higher education institutions and nonprofits. The outlined key dates indicate the program’s timeline for submissions and reviews, expiring on May 8, 2025. The announcement also stresses the importance of including appropriate biospecimens in applications, leveraging existing studies and resources to enhance the quality of research proposals. By focusing on these emerging risk factors, the NIH aims to generate evidence-based prevention strategies against liver cancer, reinforcing its commitment to advancing public health in the U.S.
    Similar Opportunities
    Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 Exploratory/Developmental Research Grant focused on epidemiologic research related to liver cancer susceptibility and emerging risk factors. This funding opportunity aims to investigate both established risk factors, such as viral hepatitis, and novel influences, including environmental and social factors, that contribute to liver cancer incidence in the United States. The initiative underscores the increasing recognition of liver cancer's rising incidence and the need for targeted public health strategies, with a funding limit of $275,000 available over two years. Interested applicants must adhere to NIH guidelines and submit their applications by May 7, 2025; for further inquiries, they can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Interventions to Address Disparities in Liver Diseases and Liver Cancer," aimed at supporting research interventions that target health disparities in liver diseases and liver cancer among marginalized populations in the United States. This initiative encourages researchers to propose multi-level and multi-domain approaches that address social determinants of health, with a focus on improving screening, treatment, and health outcomes for affected groups, including racial and ethnic minorities and individuals with lower socioeconomic status. The grant has no specific budget limit and allows for a maximum project period of five years, with applications accepted starting September 5, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering exploratory grants (R21 Clinical Trial Optional) aimed at advancing cancer control research. This funding opportunity encourages innovative approaches to understanding cancer etiology, behavior modification, and screening techniques, focusing on the early stages of impactful research that can significantly enhance population-based cancer research. Grants will provide up to $275,000 over two years, with a maximum of $200,000 available in a single year, and applications are due by October 8, 2024. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Population Approaches to Reducing Alcohol-related Cancer Risk" funding opportunity, designated as R01 Clinical Trial Optional. This initiative aims to support interdisciplinary research focused on increasing awareness of the link between alcohol consumption and cancer risk, altering social norms regarding alcohol use, evaluating alcohol policy approaches, and developing population-level interventions to mitigate alcohol-related cancer risks. The funding is particularly relevant for addressing alcohol use disorders and disparities faced by underrepresented minority populations, with applications due between January 5, 2024, and October 5, 2026, and project periods extending up to five years. There is no specific budget limit for applications, which should reflect the actual needs of the proposed projects. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-244.html.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infection in cancer development. This initiative encourages mechanistic and epidemiologic studies that explore how infections by multiple agents—both pathogenic and non-pathogenic—can influence cancer risk and progression, with a focus on known oncogenic agents, excluding HIV. Given the significant proportion of cancer cases linked to infectious agents, this research is crucial for developing novel prevention and treatment strategies. Interested applicants, including a variety of educational institutions and organizations, particularly those from underrepresented groups, must submit their applications by November 5, 2025, and can find further details and guidelines at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)." This initiative aims to establish population-based cancer epidemiology cohorts to address critical knowledge gaps in cancer etiology and survivorship, particularly focusing on engaging diverse and underserved populations. The project will support methodological work necessary for cohort development, emphasizing community engagement and the validation of cancer outcomes linked to population-based registries. Interested applicants, including educational institutions, nonprofits, and local governments, must submit their proposals by February 28, 2025, and can find additional details at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)." This grant aims to support innovative, investigator-initiated studies that explore how bariatric surgery influences cancer risk, moving beyond traditional short-term outcomes such as weight loss and diabetes management. Given the rising prevalence of obesity and the increasing number of bariatric surgeries performed in the U.S., this research is crucial for identifying new pathways for cancer prevention. The grant provides funding of up to $275,000 over two years, with applications due by January 16, 2025, and additional cycles available through 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-044.html.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research investigating the mechanisms by which bariatric surgery impacts cancer risk, under the title "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)." This initiative aims to support studies that explore the long-term effects of bariatric surgery on cancer risk, moving beyond immediate outcomes such as weight loss and diabetes, and considering factors like sex, racial background, and procedure type. With a funding ceiling of $500,000 per year for up to five years, the program encourages innovative research proposals from a diverse range of eligible applicants, including educational institutions and community organizations. Applications are due by January 7, 2028, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-043.html.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.